CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study

BACKGROUND: Tamoxifen treatment greatly reduces a woman’s risk of developing a second primary breast cancer. There is, however, substantial variability in treatment response, some of which may be attributed to germline genetic variation. CYP2D6 is a key enzyme in the metabolism of tamoxifen to its a...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Breast Cancer Res
Main Authors: Brooks, Jennifer D., Comen, Elizabeth A., Reiner, Anne S., Orlow, Irene, Leong, Siok F., Liang, Xiaolin, Mellemkjær, Lene, Knight, Julia A., Lynch, Charles F., John, Esther M., Bernstein, Leslie, Woods, Meghan, Doody, David R., Malone, Kathleen E., Bernstein, Jonine L.
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2018
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6288916/
https://ncbi.nlm.nih.gov/pubmed/30526633
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-018-1083-y
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker